Related Experiment Video
Updated: May 5, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint
Xiaoming Ju1, Mathew C Casimiro, Michael Gormley
1Authors' Affiliations: Departments of Cancer Biology, Medical Oncology, and Stem Cell Biology and Regenerative Medicine, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Abstract:
Improved clinical management of prostate cancer has been impeded by an inadequate understanding of molecular genetic elements governing tumor progression. Gene signatures have provided improved prognostic indicators of human prostate cancer. The TGF-β/BMP-SMAD4 signaling pathway, which induces epithelial-mesenchymal transition (EMT), is known to constrain prostate cancer progression induced by Pten deletion. Herein, cyclin D1 inactivation reduced cellular proliferation in the murine prostate in vivo and in isogenic oncogene-transformed prostate cancer cell lines. The in vivo cyclin D1-mediated molecular signature predicted poor outcome of recurrence-free survival for patients with prostate cancer (K-means HR, 3.75, P = 0.02) and demonstrated that endogenous cyclin D1 restrains TGF-β, Snail, Twist, and Goosecoid signaling. Endogenous cyclin D1 enhanced Wnt and ES cell gene expression and expanded a prostate stem cell population. In chromatin immunoprecipitation sequencing, cyclin D1 occupied genes governing stem cell expansion and induced their transcription. The coordination of EMT restraining and stem cell expanding gene expression by cyclin D1 in the prostate may contribute to its strong prognostic value for poor outcome in biochemical-free recurrence in human prostate cancer.
Insights
Cyclin D1 inactivation reduced prostate cancer cell growth. Endogenous cyclin D1 restrains tumor progression and expands prostate stem cells, indicating its prognostic value for patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer progression is poorly understood at the molecular genetic level, hindering clinical management.
- Gene signatures offer prognostic value, but key drivers of progression remain elusive.
- The TGF-β/BMP-SMAD4 pathway influences prostate cancer, with EMT playing a role in progression.
Purpose of the Study:
- To investigate the role of cyclin D1 in prostate cancer progression and its association with molecular signatures.
- To determine if cyclin D1 influences epithelial-mesenchymal transition (EMT) and stem cell populations.
- To evaluate the prognostic significance of cyclin D1-associated gene expression in human prostate cancer.
Main Methods:
- In vivo and in vitro studies using murine prostate and cancer cell lines to assess cyclin D1 inactivation effects.
- Analysis of molecular signatures associated with cyclin D1 in prostate cancer.
- Chromatin immunoprecipitation sequencing (ChIP-seq) to identify cyclin D1 targets.
- Correlation analysis of gene signatures with patient recurrence-free survival data.
Main Results:
- Cyclin D1 inactivation reduced cellular proliferation in both murine prostate and cancer cell lines.
- A cyclin D1-mediated molecular signature predicted poor recurrence-free survival in prostate cancer patients (HR, 3.75; P = 0.02).
- Endogenous cyclin D1 restrains TGF-β, Snail, Twist, and Goosecoid signaling, while promoting Wnt and ES cell gene expression and prostate stem cell expansion.
Conclusions:
- Cyclin D1 plays a dual role in prostate cancer by restraining EMT and expanding stem cell populations.
- The identified cyclin D1-mediated gene expression signature holds significant prognostic value for biochemical recurrence in prostate cancer.
- Understanding cyclin D1's molecular coordination offers potential therapeutic targets for improved prostate cancer management.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Anaphase Promoting Complex
Negative Regulator Molecules
Positive Regulator Molecules
Positive Regulator Molecules

